



Therapeutically Applicable Research to Generate Effective Treatments

Promoting Discoveries Leading to Cures

What is TARGET? The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative seeks to harness the power of modern genomics technologies to rapidly identify valid therapeutic targets in childhood cancers so that new, more effective treatments can be developed and ultimately bring new hope to children and their families who face the devastating burden of these diseases.

[Learn more](#)



<http://target.cancer.gov>

Areas of Research

Cancers Selected for Study


Areas for TARGET Initiative Research Focus

Underlying premise: Genes that are altered in expression, copy number, or LOH and mutation will highlight cellular pathways for therapeutic exploitation

Approach:

- High-throughput array-based technologies to comprehensively characterize genomic and transcriptomic profiles
- Gene resequencing to identify genes that are consistently altered in specific childhood cancers
- Functional validation to validate putative therapeutic targets

Cancer TARGET Initiative Strategy for ALL and Neuroblastoma Projects



Speakers for the ALL and Neuroblastoma TARGET Teams

- Stephen P. Hunger, MD (ALL TARGET)
 - Professor and Ergen Family Chair in Pediatric Cancer
 - Director, Center for Cancer and Blood Disorders
 - Chief, Pediatric Hematology/Oncology/BMT
 - University of Colorado Denver and The Children's Hospital
 - Chair, COG ALL Committee
- John M. Maris, MD (Neuroblastoma TARGET)
 - Giulio D'Angio Associate Professor of Pediatrics
 - Chief, Division of Oncology
 - Director, Center for Childhood Cancer Research
 - Children's Hospital of Philadelphia
 - University of Pennsylvania School of Medicine
 - Chair, COG Neuroblastoma Committee

Identifying More Effective Treatments for Children with Cancer

